Drug Profile
Necitumumab - Eli Lilly and Company
Alternative Names: IMC-11F8; LY 3012211; Portraza; PortrazzaLatest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer AstraZeneca; Eli Lilly and Company
- Class Antineoplastics; Fab fragments; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Solid tumours
- No development reported Colorectal cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in France (IV, Infusion)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Italy (IV, Infusion)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)